Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 Pharmaceutical 2016
"Dual
Specificity Tyrosine Phosphorylation Regulated Kinase 1A
(Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual
specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain
Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Directs, Dual Specificity Tyrosine Phosphorylation Regulated
Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or
Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase
Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2
2016, provides in depth analysis on Dual Specificity Tyrosine
Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or
MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or
HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)
targeted pipeline therapeutics.
Global
Markets Directs report features investigational drugs from across
globe covering over 20 therapy areas and nearly 3,000 indications.
The report is built using data and information sourced from Global
Markets Directs proprietary databases, company/university websites,
clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university
sites and industry-specific third party sources. Drug profiles
featured in the report undergoes periodic review following a
stringent set of processes to ensure that all the profiles are
updated with the latest set of information. Additionally, various
dynamic tracking processes ensure that the most recent developments
are captured on a real time basis.
Scope
-
The report provides a snapshot of the global therapeutic landscape
for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A
(Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual
specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain
Homolog or DYRK1A or EC 2.7.12.1)
-
The report reviews Dual Specificity Tyrosine Phosphorylation
Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein
Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein
Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted
therapeutics under development by companies and universities/research
institutes based on information derived from company and
industry-specific sources
-
The report covers pipeline products based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
-
The report features descriptive drug profiles for the pipeline
products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental
activities
-
The report reviews key players involved in Dual Specificity Tyrosine
Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or
MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or
HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1)
targeted therapeutics and enlists all their major and minor projects
-
The report assesses Dual Specificity Tyrosine Phosphorylation
Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein
Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein
Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) targeted
therapeutics based on mechanism of action (MoA), route of
administration (RoA) and molecule type
-
The report summarizes all the dormant and discontinued pipeline
projects
Reasons
to buy
-
Gain strategically significant competitor information, analysis, and
insights to formulate effective R&D strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Identify and understand the targeted therapy areas and indications
for Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A
(Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual
specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain
Homolog or DYRK1A or EC 2.7.12.1)
-
Identify the use of drugs for target identification and drug
repurposing
-
Identify potential new clients or partners in the target demographic
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Plan mergers and acquisitions effectively by identifying key players
and its most promising pipeline therapeutics
Comments
Post a Comment